PROGRESS - 医索

Abemaciclib plus fulvestrant vs fulvestrant alone for HR HER2-advanced breast cancer following progression onprior CDK46 inhibitor plus endocrine therapy Primaryoutcome of the Phase 3 postMONARCH

医客学院 - 会议报告集

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

Lorlatinib vs Crizotinib in Treatment-NaivePatients With Advanced ALK Non-SmallCell Lung Cancer 5-Year Progression-FreeSurvival and Safety From the CRoWN Study

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

Acquired gene alteration patterns and post-progressionsurvivalPARADIGM study analysis

医客学院 - 会议报告集

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

医客学院 - 其他

TROPHY-U-01 Cohort 3_Sacituzumab govitecan in combination with pembrolizumab in patients with mUC who progressed after platinum-based regimens

医客学院 - 会议报告集

Gastric cancer treatment recent progress and future perspectives

医客学院 - 其他

Cancer Cell：为何免疫治疗后某些患者的肿瘤仍然会不断进展？

近日，一篇发表在国际杂志 Cancer Cell 上题为“I ntersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy ”的研究报告中，来自密歇根大学Rogel癌症研究中心等机构的科学家们发现了一.....

学术资讯 - 临床研究

文献速览 | 活动性肺结核的诊断生物标志物：进展和挑战

Diagnostic biomarkers for active tuberculosis: progress and challengesNogueira BMF，Krishnan S，Barreto-Duarte B，Araújo-Pereira M，Queiroz ATL，Ellner JJ，Salgame P，Scriba TJ， Sterling TR，Gupta A，Andrade BB.EMBO Mo.....

学术资讯 - 临床研究